Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...

US FDA approves GSK’s Exdensur for the treatment of severe asthma: London, UK Thursday, December 18, 2025, 11:00 Hrs [IST] GSK plc announced that the US Food and Drug Administra ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

This article first appeared on GuruFocus. Analysts are increasingly focusing on GSK (NYSE:GSK) after Europe's drug regulator delivered what could be a pivotal endorsement for depemokimab, a treatment ...

Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that it has initiated two ...

BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today ...

Please provide your email address to receive an email when new articles are posted on . The median number of likes on accurate TikToks about asthma was smaller than that of inaccurate ones. Videos on ...

WASHINGTON, Sept 24 (Reuters) - The Trump administration intends to shift $1.8 billion in foreign aid funding toward "America First" initiatives such as pursuing investments in Greenland and ...

Saturday’s star-studded concert will air on TV for the first time in years as the hotline for farmers gets more calls about a mix of complicated problems. By Kevin Draper There was never supposed to ...

Weight loss injections could help to reduce asthma symptoms in obese people, according to researchers at the University of Aberdeen. The study by an international team of scientists found as well as ...

Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...